CHINOOK THERAPEUTICS INC's ticker is KDNY and the CUSIP is 16961L106. A total of 139 filers reported holding CHINOOK THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $3,934,170 | -76.8% | 102,399 | -86.0% | 0.01% | -76.9% |
| Q1 2023 | $16,949,712 | -49.0% | 732,169 | -42.2% | 0.05% | -54.0% |
| Q4 2022 | $33,212,692 | -30.8% | 1,267,660 | -48.1% | 0.11% | -41.1% |
| Q3 2022 | $47,985,000 | +13.4% | 2,440,754 | +0.9% | 0.19% | +7.3% |
| Q2 2022 | $42,310,000 | +106.2% | 2,419,099 | +92.9% | 0.18% | +121.0% |
| Q1 2022 | $20,519,000 | -46.5% | 1,254,200 | -46.7% | 0.08% | -47.1% |
| Q4 2021 | $38,357,000 | +202.1% | 2,351,743 | +136.4% | 0.15% | +173.2% |
| Q3 2021 | $12,695,000 | -39.8% | 994,870 | -33.4% | 0.06% | -41.1% |
| Q2 2021 | $21,080,000 | +15.9% | 1,492,900 | +27.6% | 0.10% | +11.8% |
| Q1 2021 | $18,185,000 | +27.8% | 1,170,198 | +30.4% | 0.08% | +23.2% |
| Q4 2020 | $14,230,000 | – | 897,246 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 5,161,888 | $135,241,466 | 29.11% |
| Octagon Capital Advisors LP | 2,551,703 | $66,854,619 | 10.41% |
| Affinity Asset Advisors, LLC | 818,035 | $21,432,517 | 8.40% |
| Frazier Life Sciences Management, L.P. | 4,345,559 | $113,853,646 | 7.08% |
| Saturn V Capital Management LP | 423,177 | $6,728,298 | 5.58% |
| Altium Capital Management LP | 385,000 | $10,087,000 | 5.13% |
| Deep Track Capital, LP | 3,000,000 | $78,600,000 | 3.30% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 340,389 | $8,914,788 | 2.75% |
| Vivo Capital, LLC | 872,151 | $22,850 | 2.63% |
| Nan Fung Group Holdings Ltd | 113,950 | $2,985,490 | 2.06% |